Description: Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.
Home Page: www.odonate.com
3 East 28th Street
New York,
NY
10016
United States
Phone:
332 206 0935
Officers
| Name | Title |
|---|---|
| Mr. Kevin C. Tang | Chairman & CEO |
| Mr. Michael S. Hearne | CFO & Principal Accounting Officer |
| Mr. Ryan Cole | Senior Vice President of Operations |
| Dr. Steven S. Pfeiffer Ph.D. | Senior Vice President of Technical Operations |
| Mr. Thomas Wei | Chief Scientific Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Financials |
|---|---|
| GIC Group: | Financial Services |
| GIC Industry: | Capital Markets |
| GIC Sub-Industry: | Asset Management & Custody Banks |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6147 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 137 |